On October 1, 2025, C4 Therapeutics, Inc. announced a collaboration with Pfizer to conduct a Phase 1b trial using Pfizer's elranatamab drug, supplied at no cost in exchange for access to trial data. This event is significant and presents a positive sentiment for investors as it enhances their clinical development efforts.